NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-03-09

Last Posted Date: 2013-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00078910

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Phase 2

Completed

Conditions: Recurrent Neuroendocrine Carcinoma of the Skin
Stage I Neuroendocrine Carcinoma of the Skin
Stage II Neuroendocrine Carcinoma of the Skin
Stage III Neuroendocrine Carcinoma of the Skin
Stage IV Neuroendocrine Carcinoma of the Skin

Interventions: Biological: oblimersen sodium
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-03-09

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00079131

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: triapine
Drug: doxorubicin hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-03-09

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00079014

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: tipifarnib

First Posted Date: 2004-03-05

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00005843

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Raltitrexed in Treating Children With Refractory Acute Leukemia

Phase 1

Completed

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions: Drug: raltitrexed

First Posted Date: 2004-03-01

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00003528

Locations: 🇨🇭
Swiss Pediatric Oncology Group - Geneva, Geneva, Switzerland

Docetaxel in Treating Children With Recurrent Solid Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Neuroblastoma
Sarcoma

Interventions: Biological: filgrastim
Drug: docetaxel

First Posted Date: 2004-03-01

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00002825

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 33 locations

BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma

Phase 2

Terminated

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions: Drug: ixabepilone

First Posted Date: 2004-02-27

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00022542

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation
Refractory Anemia With Ringed Sideroblasts
Secondary Myelodysplastic Syndromes

Interventions: Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2004-02-27

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00015990

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

SU5416 in Treating Patients With Malignant Mesothelioma

Phase 2

Completed

Conditions: Malignant Mesothelioma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00006014

Locations: 🇺🇸
Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 7 locations

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2004-02-20

Last Posted Date: 2013-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1800

Registration Number: NCT00003240

Locations: 🇬🇧
Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy